rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study
Status:
Completed
Trial end date:
2023-09-27
Target enrollment:
Participant gender:
Summary
The study is designed as a randomized, two-armed, double-blind, single-dose, crossover,
two-sequence, active-controlled, multi-center, bioequivalence clinical trial with a primary
endpoint of dose-normalized area under the curve (dnAUC last)